Mast-Cell Stabilizing Effects of Olopatadine

Alcon

Status and phase: Completed; Phase 4

Conditions: Allergic Conjunctivitis

Treatments: Drug: Olopatadine (generic name)

Study type: Interventional

Funder types: Industry

Identifiers

NCT00389025

C-05-30

Details and patient eligibility

About

To assess the effects of olopatadine of the release of mast cell histamine

Enrollment: 24 patients

Sex: All

Ages: 18+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Asymptomatic and not using any topical or systemic medication

Exclusion criteria

• Age

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Single Group Assignment

Masking: Double Blind